BioCentury
ARTICLE | Clinical News

BioDelivery falls on Phase III miss

March 31, 2015 1:06 AM UTC

BioDelivery Sciences International Inc. (NASDAQ:BDSI) shed $3.38 (24%) to $10.51 on Monday after its clonidine topical gel ( ARC-4558) missed the primary endpoint in a Phase III trial to treat painful diabetic neuropathy (PDN).

In the trial, patients treated with clonidine topical gel did not experience a statistically significant change in average Numeric Pain Rating Scales (NPRS) compared to those who received placebo. BioDelivery said the trial did meet secondary endpoints, including a statistically significant improvement in pain symptoms as measured by the Neuropathic Pain Symptom Inventory (p=0.05) and quality of life as measured by the EuroQOL Questionnaire (p=0.04). ...